Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant

NCT02945150 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT02945150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02945150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2017
Completion date
March 5, 2020
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal failure